Biomedical subjects

Sirima Pattamadilok

Publications and source records attributed to Sirima Pattamadilok.

3 recordsLinked to original sources

PubMed2006

Development of serological assays for Thottapalayam virus, an insectivore-borne Hantavirus.

Thottapalayam virus (TPMV), a member of the genus Hantavirus in the family Bunyaviridae, was isolated from an insectivore, Suncus murinus (musk shrew), captured in southern India in 1964. While the isolation of TPMV predates the discovery of the prototype Hantaan virus, little is known about its genetics and biology. To date, preliminary evidence suggests that TPMV differs significantly, both antigenically and genetically, from all known rodent-borne hantaviruses. However, since detailed epizootiological studies have not been conducted, it is unclear if TPMV is naturally harbored by an insectivore host or if TPMV represents a "spillover" from its natural rodent reservoir host. Moreover, to what extent TPMV causes infection and/or disease in humans is not known. To address these issues, we first studied the antigenic profile of TPMV using monoclonal antibodies against Hantaan and Seoul viruses and polyclonal immune sera against Puumala virus and TPMV. Armed with this newfound information, we developed an enzyme-linked immunosorbent assay system for the diagnosis of TPMV infections in shrews and humans, using a recombinant TPMV N antigen manipulated to have an E5/G6 epitope to be captured by monoclonal antibody clone E5/G6. Using this assay, we found anti-TPMV antibodies in sera from a patient with high fever of unknown etiology in Thailand and from two shrews captured in Indonesia. Seropositivity was verified by the indirect immunofluorescence antibody test, Western blotting analysis, and focus reduction neutralization test. Collectively, our data indicate that TPMV is harbored by Suncus murinus as its host in nature and is capable of infecting humans.

Animals↗

PubMed2006

Geographical distribution of hantaviruses in Thailand and potential human health significance of Thailand virus.

Phylogenetic investigations, sequence comparisons, and antigenic cross-reactivity studies confirmed the classification of Thailand virus (THAIV) as a distinct hantavirus species. The examination of sera from 402 rodents trapped in 19 provinces of Thailand revealed that five greater bandicoot rats (Bandicota indica) and one lesser bandicoot rat (B. savilei) from four provinces were focus reduction neutralization test (FRNT) antibody-positive for THAIV. One of 260 patients from Surin province in Thailand (initially suspected of having contracted leptospirosis, but found to be negative) showed symptoms compatible with hemorrhagic fever with renal syndrome (HFRS). The serum of this patient showed high titers of hantavirus-reactive IgM and IgG. FRNT investigations confirmed virus-neutralizing antibodies against THAIV. These observations suggest that THAIV or THAI-like viruses occur throughout Indochina and may represent an additional causative agent of HFRS.

Animals↗

PubMed2003

Antibody response after measles immunization.

RATIONALE: Measles is still an important public health problem in Thailand despite measles vaccination being practiced since 1984. Vaccine failure is one of the suspected reasons for the high incidence of measles. OBJECTIVE: To study the seroconversion rate of 9-month-old infants and to study the antibody level in 18 month-old and 4 year-old children who had measles vaccination at 9 months of age. MATERIAL AND METHOD: Enrolled infants and children who attended the child health clinic for routine immunization at the Queen Sirikit National Institute of Child Health from March 1, 1994 to May 31, 1995. They were divided into 3 groups. Group A, 9 month-old infants who came for measles vaccination. Blood samples were drawn twice from these infants, before measles vaccination and 3 months later for measles antibody level. Group B and C were 18 month-old and 4-year-old children who came for their first and second DTP (Diphtheria, Tetanus, Pertussis vaccine) booster. One blood sample for measles antibody was drawn from the latter group of children. Measles antibody was determined by micro-neutralization technic at the National Institute of Health (NIH). The geometric mean antibody titer before and after measles vaccination was compared by using the paired t-test. RESULTS: There were 30, 31 and 34 infants/children in group A, B and C respectively. No significant measles antibody (NT antibody was less than 1:4) was detected in 93.5 per cent of 9-month-old infants. The seroconversion rate at 3 months after vaccination in group A children was 68.75 per cent while in group B, 9 months after vaccination it was 53.3 per cent. Ninety seven per cent of children in group C had NT antibody above 1:4. The geometric mean titer (GMT) of measles antibody in 9-month (before vaccination), 12-month, 18-month infants and 4 year old children was 1:2.5; 1:14.8, 1:8.2 and 1:73.8, respectively (p < 0.05). CONCLUSION: Almost 70 per cent of vaccinees at 9 months of age had seroconversion to measles vaccine with GMT of 1:14.8 while fifty three per cent of 18 month old children had an average GMT of 1:8.2. The GMT of the two groups was significantly different (p < 0.05). At 4 years of age almost all the children had NT antibody to measles with a GMT of 1:73.8 (p < 0.05) Vaccine failure is likely to be one factor responsible for the high incidence of measles after the introduction of measles vaccine into the Expanded Program of Immunization (EPI). The authors suggest giving a booster dose of measles at 15 months of age to boost the antibody level before waning of measles antibody at 18 months old, in order to protect this group of children from contracting measles.

Antibodies, Viral↗